DUVELISIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H17ClN6O
Molecular Weight	416.863
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](NC1=C2N=CNC2=NC=N1)C3=CC4=C(C(Cl)=CC=C4)C(=O)N3C5=CC=CC=C5

InChI

InChIKey=SJVQHLPISAIATJ-ZDUSSCGKSA-N

InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C22H17ClN6O
Molecular Weight	416.863
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://adisinsight.springer.com/drugs/800035173
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24211136

Duvelisib (IPI-145), is an orally available, small-molecule, selective dual inhibitor of phosphatidylinositol 3 kinase (PI3K) δ and γ isoforms originated by Intellikine (owned by Takeda) and developed by Infinity Pharmaceuticals. Orally administered duvelisib was rapidly absorbed, with a dose-proportional increase in exposure. The compound produced a half-life of approximately 7-12 hours, following 14 days of dosing. Duvelisib exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation. Duvelisib blockade of PI3K-δ and PI3K-γ potentially lead to significant therapeutic effects in multiple inflammatory, autoimmune, and hematologic diseases. The molecule is in phase III development as a combination therapy for patients with haematological malignancies such as chronic lymphocytic leukemia and follicular lymphoma.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
PI3-kinase p110-delta subunit 43 Target ID: CHEMBL3130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24211136	Inhibitor 8228		2.5 nM [IC50]
PI3-kinase p110-gamma subunit 32 Target ID: CHEMBL3267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24211136	Inhibitor 8228		27.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	Primary		Approved 8360	COPIKTRA Approved Use COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with: • Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. • Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Launch Date 1.53766081E12
Relapsed or refractory follicular lymphoma 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	Primary		Approved 8360	COPIKTRA Approved Use COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with: • Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. • Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Launch Date 1.53766081E12

C_max

Value	Dose	Co-administered	Analyte	Population
1062 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033052/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		DUVELISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.5 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	50 mg 2 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DUVELISIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
7098.4 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033052/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		DUVELISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.9 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	50 mg 2 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DUVELISIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033052/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:		DUVELISIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	50 mg 2 times / day steady-state, oral dose: 50 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DUVELISIB unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg 2 times / day steady, oral Highest studied dose Dose: 100 mg, 2 times / day Route: oral Route: steady Dose: 100 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29191916	unhealthy, 66.5 years (range: 25-86 years) n = 2 Health Status: unhealthy Age Group: 66.5 years (range: 25-86 years) Sex: M+F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/29191916	DLT: Alanine aminotransferase increase, Aspartate aminotransferase increased... Dose limiting toxicities: Alanine aminotransferase increase (grade 3, 1 patient) Aspartate aminotransferase increased (grade 3, 1 patient) Rash (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29191916
75 mg 2 times / day steady, oral MTD Dose: 75 mg, 2 times / day Route: oral Route: steady Dose: 75 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29191916	unhealthy, 66.5 years (range: 25-86 years) n = 6 Health Status: unhealthy Age Group: 66.5 years (range: 25-86 years) Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/29191916	DLT: Cellulitis... Dose limiting toxicities: Cellulitis (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29191916
15 mg 2 times / day steady, oral Dose: 15 mg, 2 times / day Route: oral Route: steady Dose: 15 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29191916	unhealthy, 66.5 years (range: 25-86 years) n = 7 Health Status: unhealthy Age Group: 66.5 years (range: 25-86 years) Sex: M+F Population Size: 7 Sources: https://pubmed.ncbi.nlm.nih.gov/29191916	DLT: Neutropenia... Dose limiting toxicities: Neutropenia (grade 4, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/29191916
25 mg 2 times / day steady, oral Recommended Dose: 25 mg, 2 times / day Route: oral Route: steady Dose: 25 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf Page: p. 137	unhealthy, 67 years (range: 30 - 90 years) n = 442 Health Status: unhealthy Condition: Hematologic Malignancies Age Group: 67 years (range: 30 - 90 years) Sex: M+F Population Size: 442 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf Page: p. 137	Disc. AE: Transaminases increased, Sepsis... AEs leading to discontinuation/dose reduction: Transaminases increased (1%) Sepsis (1%) Transaminases increased (4%) Neutropenia (3%) Febrile neutropenia (2%) Lipase increased (1%) Diarrhea (19%) Colitis (19%) Rash (8%) Pneumonia (10%) Neutropenia (8%) Transaminases increased (6%) Pyrexia (4%) Anemia (3%) Febrile neutropenia (3%) Lipase increased (3%) Thrombocytopenia (3%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf Page: p. 137
25 mg 2 times / day steady, oral Recommended Dose: 25 mg, 2 times / day Route: oral Route: steady Dose: 25 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	unhealthy, 69 years (range: 39 - 90 years n = 158 Health Status: unhealthy Condition: CLL or SLL Age Group: 69 years (range: 39 - 90 years Sex: M+F Population Size: 158 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	Disc. AE: Diarrhea, Colitis... AEs leading to discontinuation/dose reduction: Diarrhea (36%) Colitis (36%) Infection (36%) Rash (36%) Diarrhea (29%) Colitis (29%) Rash (29%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf
75 mg 2 times / day steady, oral MTD Dose: 75 mg, 2 times / day Route: oral Route: steady Dose: 75 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30033575	unhealthy, 70 years (range: 42-78) n = 15 Health Status: unhealthy Age Group: 70 years (range: 42-78) Sex: M+F Population Size: 15 Sources: https://pubmed.ncbi.nlm.nih.gov/30033575	Other AEs: ALT increased, AST increased... Other AEs: ALT increased (grade 3-4, 40%) AST increased (grade 3-4, 13.3%) Neutropenia (grade 3-4, 33.3%) Anemia (grade 3, 13.3%) Diarrhea (grade 3, 33.3%) Pyrexia (grade 3, 6.7%) Nausea (grade 3, 6.7%) Rash maculo-papular (grade 3, 13.3%) Thrombocytopenia (grade 1-2, 13.3%) Fatigue (grade 1-2, 46.7%) Cough (grade 1-2, 46.7%) Headache (grade 1-2, 26.7%) Decreased appetite (grade 1-2, 26.7%) Dyspnoea (grade 1-2, 40%) Rash (grade 1-2, 26.7%) Upper respiratory tract infection (grade 1-2, 13.3%) Vomiting (grade 1-2, 6.7%) Chills (grade 1-2, 13.3%) Myalgia (grade 1-2, 26.7%) Edema peripheral (grade 1-2, 26.7%) Oropharyngeal pain (grade 1-2, 20%) Stomatitis (grade 1-2, 26.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/30033575
25 mg 2 times / day steady, oral Recommended Dose: 25 mg, 2 times / day Route: oral Route: steady Dose: 25 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf	Other AEs: Infection, Diarrhea... Other AEs: Infection (grade 5\|serious, 31%) Diarrhea (grade 5\|serious, 18%) Colitis (grade 5\|serious, 18%) Epidermal and dermal conditions (grade 5\|serious, 5%) Pneumonitis (grade 5\|serious, 5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1709 inhibitor 1579	substrate 1010	substrate 1193	inhibitor 1599

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C8 901 OCT1 506 OATP1B1 781 OATP1B3 700 MATE1 304 MATE2 261 BSEP 401 BCRP 691 P-gp 1437 OAT1 595 OAT3 636 OCT2 638	CYP1A2 1032 CYP2B6 660 CYP2C8 688 CYP2C19 985 CYP2E1 648

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
BCRP 765	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	no	IPI-656 2
OAT1 599	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	no
OAT3 638	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	no
OAT3 638	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	no	IPI-656 2
OCT1 523	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	no	IPI-656 2
OCT2 639	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	no
OCT2 639	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	no	IPI-656 2
P-gp 1626	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	no	IPI-656 2
BCRP 765	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes
BSEP 402	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes
BSEP 402	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes	IPI-656 2
CYP2C8 955	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=64 Page: 64.0	yes
CYP2C8 955	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=64 Page: 64.0	yes	IPI-656 2
MATE1 306	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes
MATE1 306	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes	IPI-656 2
MATE2 261	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes
MATE2 261	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes	IPI-656 2
OATP1B1 796	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes
OATP1B1 796	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes	IPI-656 2
OATP1B3 709	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes
OATP1B3 709	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes	IPI-656 2
OCT1 523	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes
P-gp 1626	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=67 Page: 67.0	yes
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=64 Page: 64.0	yes		yes (co-administration study) Comment: In a dedicated drug-interaction trial in healthy subjects, midazolam (a CYP3A4 substrate) single dose Cmax and AUC were increased by 120% and 330% respectively, when co-administered with duvelisib ( Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=64 Page: 64.0
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=64 Page: 64.0	yes	IPI-656 2	yes (co-administration study) Comment: In a dedicated drug-interaction trial in healthy subjects, midazolam (a CYP3A4 substrate) single dose Cmax and AUC were increased by 120% and 330% respectively, when co-administered with duvelisib ( Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=64 Page: 64.0

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C19 985	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0	no
CYP2C8 688	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0	no
CYP2C9 1010	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0	no
CYP2D6 1193	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0	no
CYP2E1 648	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0	no
CYP1A2 1032	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0	yes
CYP2B6 660	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0	yes
CYP3A4 1709	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0	yes	yes (co-administration study) Comment: In a dedicated drug-interaction trial in healthy subjects (N=16), concomitant ketoconazole (a strong CYP3A4 inhibitor and P-gp inhibitor) increased duvelisib Cmax and AUC by 66% and 295% respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=39 Page: 39.0

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1632	inhibitor 1613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=37 Page: 37.0
hERG 1632	inhibitor 1613 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000MultidisciplineR.pdf#page=37 Page: 37.0		IPI-656 2

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA000QBA	https://www.aablocks.com/goods/Goods/detail?id=AA000QBA
AEchem Scientific Corp., USA	AE049569	http://www.aechemsc.com/info_products/AE049569.php
AK Scientific, Inc. (AKSCI)	SYN1175	http://www.aksci.com/item_detail.php?cat=SYN1175
AK Scientific, Inc. (AKSCI)	X5816	http://www.aksci.com/item_detail.php?cat=X5816
Aaron Chemicals	AR000R32	http://www.aaronchem.com/1201438-56-3
AbMole Bioscience	M2073	http://www.abmole.com/products/ipi-145.html
Achemtek	0102-014564	http://www.achemtek.com/1201438-56-3
Adooq BioScience	A12422	https://www.adooq.com/ipi-145.html
Alsachim	4863	http://www.alsachim.com/product-C6244-glo.bal-view.html
Angene	AGN-PC-0WADI8	http://www.angenechemical.com/productshow/AGN-PC-0WADI8.html
Aurora Fine Chemicals LLC	A24.096.501	http://online.aurorafinechemicals.com/info?ID=A24.096.501
Aurum Pharmatech LLC	W-5592	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5592
AvaChem Scientific	6294	https://www.avachem.com/productSearch.asp?6294
BioChemPartner	BCP07042	http://www.biochempartner.com/1201438-56-3-BCP07042
BioCrick	BCC1104	http://www.biocrick.com/IPI-145-INK1197-BCC1104.html
Boerchem	BC600328	http://www.boerchem.com/?product_43163.html
Chem Scene	CS-0888	http://www.chemscene.com/1201438-56-3.html
Chemspace	CSSB00015189272	https://chem-space.com/CSSB00015189272
DC Chemicals	DC5072	http://www.dcchemicals.com/product_show-Duvelisib_IPI_145_INK1197_.html
Excenen	EX-A1562	http://www.excenen.com/searchresultlist.php?id=1201438-56-3
Hairui	DUSA062	http://www.hairuichem.com/en/product/1201438-56-3.html
Lab Network	LN01287724	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01287724
Matrix Scientific	145387	https://www.matrixscientific.com/145387.html
MedChem Express	HY-17044	https://www.medchemexpress.com/Duvelisib.html
Smolecule	S548996	http://www.smolecule.com/products/s548996
Sun-shine Chemical	Duvelisib	http://www.sun-shinechem.com/1201438-56-3.html
Synblock Inc	SB16470	http://www.synblock.com/product/1201438-56-3.html
THE BioTek	bt-287271	https://www.thebiotek.com/product/inhibitors/bt-287271
Yuhao Chemical	RT2409	http://www.chemyuhao.com/1201438-56-3.html
abcr GmbH	AB479625	http://www.abcr.com/shop/en/AB479625
eNovation Chemicals	D372449	http://www.enovationchem.com/productDetails.asp?productID=D372449
eNovation Chemicals	D663043	https://www.enovationchem.com/ProductDetails.asp?ProductID=D663043
eNovation Chemicals	Y0974910	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0974910

PubMed

Title	Date	PubMed
PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.	2013 Nov 21	24211136
Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis.	2014 Feb	24244039
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.	2015 Sep	25917267
Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.	2016 Jun 28	27174919

Patents

Sample Use Guides

In Vivo Use Guide

25-75 mg twice daily for five to 28 days

Route of Administration: Oral

In Vitro Use Guide

0.25 to 5 uM IPI-145 exhibited concentration- and time-dependent induction of cytotoxicity in primary chronic lymphocytic leukemia cells

Substance Class	Chemical Created by `admin` on `Thu Jul 06 07:58:58 UTC 2023` Edited by `admin` on `Thu Jul 06 07:58:58 UTC 2023`
Record UNII	610V23S0JI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DUVELISIB

Official Name

English

1(2H)-ISOQUINOLINONE, 8-CHLORO-2-PHENYL-3-((1S)-1-(9H-PURIN-6-YLAMINO)ETHYL)-

Systematic Name

English

IPI-145

Code

English

Duvelisib [WHO-DD]

Common Name

English

duvelisib [INN]

Common Name

English

(S)-3-(1-(9H-PURIN-6-YLAMINO)ETHYL)-8-CHLORO-2-PHENYLISOQUINOLIN-1(2H)-ONE

Systematic Name

English

DUVELISIB [MI]

Common Name

English

INK-1197

Code

English

DUVELISIB [ORANGE BOOK]

Common Name

English

DUVELISIB [USAN]

Common Name

English

INK-1147

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C2152